Global Orphan Drugs Market Drivers, Restraints, Potential Growth Opportunities, Vendor Competitive Landscape, Trends and Forecast 2020-2030

At a compound annual growth rate (CAGR) of 11.6%, the size of the global orphan drug market is anticipated to increase from $170.49 billion in 2023 to $368.43 billion by 2030.

That have cumulated and amplified the global orphan drugs market size includes rising prevalence of cancer patients and increased growth of oncology segment, development of early diagnostic techniques and government incentives for orphan medicine. In regions like U.S. and Europe, there has been ongoing exclusive marketing for more than decade. Along with that, regulatory bodies’ tie-ups with research institutes has helped promoting the R&D on rare disease. For instance, National Organization for rare disease (NORD) empowers to cater the technical and scientific information related to rare diseases. These conducts offer information of medication and patient assistance programs. However, the factor that may inhibit the market growth is high cost of development of drugs and lack of awareness regarding the treatment and availability of drugs and treatments.

The global orphan drugs market is classified by top selling drugs, type, geographical terrain and therapeutic area. The type segment is classified into metabolic diseases, neurologic diseases, infectious diseases, oncologic diseases, hematologic & immunologic diseases and other rare diseases. The most dominant segment of disease type is oncologic diseases as recorded in 2015. Additionally, it is envisioned that the trend will continue during the forecast period. The cause behind is the array of different forms of rare cancers like myeloma, angiosarcoma, leukemia, and others prevalent ones in the patient population.

North America dominates the global orphan drugs market backed by its favorable government regulations and highly developed healthcare infrastructure. In North America, the U.S.A. accounts the largest market share due to rising awareness and economic incentives leading to higher growth of orphan drugs market. Further, higher investments to diagnose and treat the rare disease also helps the growth of orphan drug market.

Earlier times, these drugs applications were mainly for treating the population suffering from serious illness but rare diseases for which proper treatment was not available. There were approximately 25 to 30 million people are affected by this disease in Europe. Global orphan drug awareness has heightened which further leads higher adoption in Australia, Japan, Europe and other nations to stimulate research and development in the orphan drug.

The global orphan drugs market is anticipated to have competitive environment among the leading players across the globe. Prompt increase in number of players that are expected enter the market in the upcoming years are likely to augment the competitiveness. In the recent past years, there is considerable rise in the development of drugs along with rapid development biopharmaceutical sector are supposed to strengthen the market growth in the next couple of years. Additionally, escalated investments accomplished by the leading players for the research activities is expected to develop higher growth opportunities, which in turn widen the global orphan drugs market size. The leading international players engaged in orphan drugs are Alexion Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Shire plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Biogen Inc., Johnson & Johnson, Amgen Inc., AstraZeneca plc., Bayer AG, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., Novo Nordisk A/S, Merck & Co. Inc., and Celgene Corporation.

Orphan Drugs Market Scope

Key segments of ‘Global Orphan Drugs Market’

Based on indication, the market has been segmented into,

• Non-Hodgkin Lymphoma
• Acute Myeloid Leukemia
• Cystic Fibrosis
• Glioma
• Pancreatic Cancer
• Ovarian Cancer
• Multiple Myeloma
• Duchenne Muscular Dystrophy
• Graft vs Host Disease
• Renal Cell Carcinoma
• Others

Based on disease type, the market has been segmented into,

• Oncologic Diseases
• Metabolic Diseases
• Hematologic and Immunologic Diseases
• Infectious Diseases
• Neurologic Diseases
• Other Rare Diseases

Based on region, the market has been segmented into,

• North America
  • U.S.
  • Canada
  • Mexico
• Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

• Asia-Pacific
  • India
  • Australia
  • South Korea
  • Taiwan
  • Japan
  • China
• LAMEA

• Brazil
• Turkey
• Saudi Arabia
• South Africa
• Rest of LAMEA